TIKTOK
6.9.2018 12:57:28 CEST | Business Wire | Press release
TikTok, the go-to destination for the creating and viewing short-term mobile videos, has arrived in the global capital of fashion: Paris. The worldwide phenomenon held its first event on Tuesday September 4 during a unique night on the Seine. With its “80’s vs 2080 theme, TikTok took its community on a creative and innovative adventure, like its platform. The brand also welcomed today’s most creative influencers to celebrate the arrival of the new TikTok platform, born from the union with the Musical.ly app, and has thus unveiled application’s new innovative features and technological innovations of the application, such as "reaction" function that allows users to react directly to their friends' videos.
TikTok : a new groundbreaking upgrade
A global platform now
present in more than 150 countries and regions, TikTok was one of the
most downloaded applications in the world in early 20181
. The
latest update, which incorporates the best of both applications, has
allowed TikTok to creatively connect its community in a multicultural
environment. The newly upgraded platform, offers greater capabilities
for video creation and allows creators to enjoy the opportunity to reach
a bigger and more diverse global audience. By providing an intuitive,
creative and personalized visualization experience, TikTok enables its
community to create and discover tomorrow's trends
Chenyi Qiu, Director of TikTok Operations in West Europe, said: "The rebranding of TikTok in Europe marks a new milestone for us! Through this event we wish to celebrate the diversity of our platform and thus put creativity in the spotlight in different sectors. That is why we approach the theme of sustainable fashion with our community. "
TikTok inspires the best creators and influencers
For the
launch of the new TikTok platform in France, the application paid
tribute to the creativity of its community by organizing original
workshops. To make this moment a memorable evening, TikTok partnered
with the best, and invited creators from different horizons: fashion,
music, dance, makeup, ...
Claire Dartigues, fashion designer and finalist of the 2017 Redress Award, gave a workshop on the importance of sustainable fashion. Claire also inspired her audience by showing them how to create a unique and original outfit entirely made of recyclable materials. During another workshop, TikTok’s influencers and creators unveiled the breadth of their creativity and shared their best tips for creating innovative and creative videos.
Much more than just videos!
With the help of many
influencers including Youtuber Shera
Kerienski
and influencer Estelle
Fitz
, the app unveiled many of the application’s new features.
TikTok presented the "reaction" function
which allows
the user to react directly to their friends’ videos on their phone. This
innovative technology allows users to interact with videos by
integrating their reactions into the content they are viewing. The
platform also unveiled its new
interactive filters made possible by artificial intelligence
,
allowing users to apply filters to their entire body and trigger new
special effects. Rachel
Ward
, famous influencer from TikTok, said : "TikTok is a great app
because it gave me the courage to be myself and have fun the community
is supportive, friendly and diverse."
About TikTok
TikTok is a
destination for short-form mobile videos. Our mission is to capture and
present the world's creativity, knowledge, and moments that matter,
directly from the mobile phone. TikTok enables everyone to be a creator
and encourages users to share their passion and creative expression
through their videos. TikTok is based in Los Angeles, with global
offices in London, Tokyo, Seoul, Shanghai, Beijing, Singapore, Jakarta,
Mumbai, and Moscow. In early 2018, TikTok was one of the most downloaded
apps in the world. TikTok is available worldwide for iOS
and Android
. Visit tiktok.com
.
1 Sensor tower, 1Q report
View source version on businesswire.com: https://www.businesswire.com/news/home/20180906005390/en/
Contact:
Agence Burson Cohn&Wolfe Giulia Goodwin - Charlotte Durand tiktokfr@cohnwolfe.com +33 (0)1 56 03 13 83 / +33 (0)6 28 79 11 40 +33 1 56 03 13 66
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom